We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction.
- Authors
Cheng, Jia-Rong; Hui, Hai-Zheng; Zheng, Jie; Mao, Han; Wang, Ying-Jun; Shi, Bing-Jun
- Abstract
Amivantamab has been granted accelerated approval by the FDA for the treatment of non-small cell lung cancer with specific genetic mutations. However, a case study reported an adverse cutaneous reaction in a patient receiving amivantamab treatment. The patient developed skin lesions on the face, scalp, buttocks, and lower limbs, along with other symptoms such as skin pain and nail changes. The adverse events were treated with topical medications and improved after a week, but recurred with subsequent infusions of amivantamab. While amivantamab has shown efficacy in treating lung cancer, it is important to understand and manage its potential cutaneous side effects.
- Subjects
BISPECIFIC antibodies; ITCHING; EPIDERMAL growth factor receptors; NON-small-cell lung carcinoma
- Publication
Indian Journal of Dermatology, Venereology & Leprology, 2024, Vol 90, Issue 1, p1
- ISSN
0378-6323
- Publication type
Article
- DOI
10.25259/IJDVL_717_2022